The known importance of androgens in the pathogenesis of BPH/BPE, the potential role of CYP19A1 in androgen metabolism, and the association between both polymorphisms and BPH risk prompted us to investigate the association between genetic polymorphisms in the CYP19A1 gene and several clinical and laboratory BPH parameters in a population‐based sample. This evidence concerns the gene CYP19A1 and benign prostatic hyperplasia.